Navigation Links
Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022
Date:12/4/2013

London (PRWEB) December 04, 2013

Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

Summary

Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics.

Vaniprevir, formerly MK-7009, is an HCV therapy being developed by Merck. Vaniprevir is a protease inhibitor. The HCV protease is required for viral polyprotein processing, which makes the enzyme essential for HCV replication (Asselah and Marcellin, 2013). Inhibitors of the HCV protease are, therefore, attractive antiviral drugs.

Scope

-Overview of Hepatitis C, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on Vaniprevir including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for Vaniprevir for the top nine countries from 2012 to 2022.
-Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, India and China.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Hepatitis C
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of Vaniprevir performance
-Obtain sales forecast for Vaniprevir from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, India and China).

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
2.3 Upcoming Related Reports 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.2 Symptoms 15
4 Disease Management 16
4.1 Diagnosis and Referral Overview 16
4.2 Treatment Overview 17
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 22
6.1 Overview 22
6.2 Unmet Needs 23
6.2.1 Unmet Need: Treatment Tolerability 23
6.2.2 Unmet Need: Efficacy 23
6.2.3 Unmet Need: Disease Awareness 24
6.2.4 Unmet Need: Treatment Cost 25
6.2.5 Unmet Need: Shorter Treatment Duration 25
6.2.6 Unmet Need: Simplified Treatment Regimens 26
6.3 Unmet Needs Gap Analysis 26
6.4 Opportunities 27
6.4.1 Opportunity: Pan-genotypic HCV Regimen 27
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 27
6.4.3 Opportunity: Involvement of Immune System 28
7 Pipeline Assessment 29
7.1 Overview 29
7.2 Promising Drugs in Clinical Development 30
8 Vaniprevir 32
8.1 Overview 32
8.2 Efficacy 33
8.3 Safety 34
8.4 Dosing and Formulation 34
8.5 Potential Clinical Positioning 34
8.6 Potential Commercial Positioning 34
8.7 Pricing and Reimbursement 35
8.8 SWOT Analysis 35
8.9 Forecast 36
9 Appendix 38
9.1 Bibliography 38
9.2 Abbreviations 40
9.3 Methodology 41
9.4 Forecasting Methodology 41
9.4.1 Percent Drug-Treated Patients 41
9.4.2 Patient Warehousing 42
9.4.3 General Pricing Assumptions 42
9.4.4 Generic Erosion 43
9.4.5 Pricing of Pipeline Agents 43
9.5 Physicians and Specialists Included in this Study 44
9.6 Survey of Prescribing Physicians 46
9.7 About the Authors 47
9.7.1 Author 47
9.7.2 Global Head of Healthcare 47
9.8 About GlobalData 48
9.9 Contact Us 48
9.10 Disclaimer 48

1.1 List of Tables

Table 1: Modes of HCV Transmission 14
Table 2: Symptoms of Acute and Chronic HCV Infection 15
Table 3: HCV Genotypes Present in the 9MM 17
Table 4: General Standard of Care by HCV Genotype 17
Table 5: Treatment Guidelines for HCV by Country 18
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 19
Table 7: Leading Treatments for HCV, 2012 21
Table 8: Overall Unmet Needs – Current Level of Attainment 22
Table 9: Clinical Unmet Needs – Gap Analysis, 2012 26
Table 10: HCV – Pipeline, 2012 30
Table 11: Comparison of Therapeutic Classes in Development for HCV, 2012 31
Table 12: Merck’s Vaniprevir Ongoing Clinical Trials of Interest 32
Table 13: Product Profile – Vaniprevir 33
Table 14: Vaniprevir SWOT Analysis, 2012 36
Table 15: Global Sales Forecasts ($m) for Vaniprevir, 2012–2022 37
Table 16: Physicians Surveyed, By Country 46

1.2 List of Figures

Figure 1: HCV Genome and Polyprotein Composition 11
Figure 2: HCV Lifecycle Overview 12
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012–2022 30

Read the full report:

Vaniprevir (Hepatitis C Virus) - Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/vaniprevir_hepatitis_virus_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Read the full story at http://www.prweb.com/releases/2013/12/prweb11393046.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. USA Payday Forever Forecasts Delay Of Personal Finance Help Documents For Their Website
2. Flu outbreaks predicted with weather forecast techniques
3. New Report on Water Treatment Equipment Market - by Technology, Application & Geography - Forecasting to 2017 will be Published by MarketsandMarkets
4. Astro Clairvoyant Norah Guide for Premium Astrology Now Provides Daily Forecasts and Daily Tarot Readings at No Cost
5. Dana Point Real Estate Market Forecast 2013 Released by Sam Smith
6. Canada In Vitro Diagnostics Market Analysis and Forecasts to 2017 in New Research Report at RnRMarketResearch.com
7. BRICS Mobility Aids and Transportation Equipment Market Analysis & 2018 Forecasts in New Research Report at RnRMarketResearch.com
8. Indian Nutraceuticals Market Forecast to 2017
9. Brain Monitoring Market By Product & Application: Global Forecasts to 2017 - Market to reach $1.63 billion by 2017
10. Research and Markets Announces the Release of Global Biobank (Biospecimen/Biorepository/Biopreservation) Market For Equipment & Media – Trends & Forecast to 2017
11. Global Atherectomy and Thrombectomy Devices Market 2012-2016 - World Atherectomy and Thrombectomy Devices Industry Share, Size, Trends, Analysis and Forecast to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: